
BioCorRx Inc.
73
Recent news coverage includes general market and sector-related topics but does not provide direct updates on BioCorRx Inc.'s business activities.
- Wheat prices increased following a Ukrainian strike, impacting agricultural commodity markets [N1].
- Corn prices extended gains in early trading sessions [N2].
- Air Industries Group disavowed a press release related to Tenax Aerospace dated November 16, 2026 [N3].
- Dermata Therapeutics reported over 1,000 orders for its Tome foundational treatment [N4].
- Essential Properties Realty Trust detailed its capital plan and investment activity for Q4 2026 [N5].
- Disney announced a 33% increase in its dividend, citing underlying business drivers [N6].
- Elon Musk expressed intent to maintain 25% voting control of Tesla to lead AI initiatives [N7].
- ANZ Group reported a rise in Q3 cash profit [N8].
BioCorRx Inc. is a publicly traded company identified by ticker BICX. The company has recent SEC filings providing detailed financial data through Q3 2026. The financial snapshot reveals negative revenue and net income for the latest quarter, alongside significant current liabilities exceeding current assets, resulting in low liquidity ratios. Publicly available information does not specify the company's sector, industry, or geographic focus. Recent news coverage includes general market and sector-related topics but lacks direct updates on BioCorRx's business activities.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. BioCorRx Inc. reported a net loss of $797,134 and negative revenue of $40,348 for the quarter ending September 30, 2026. The company had cash and equivalents of $111,461 and current assets of $528,740 against current liabilities of $9,181,525, resulting in a low current ratio of 0.06 and cash ratio of 0.01, indicating liquidity challenges [S2].
The company maintains some cash and current assets, which could support ongoing operations despite current liabilities exceeding assets. The presence of basic earnings per share reported positively suggests some shareholder value metrics are tracked. If operational improvements occur, the company might stabilize its financial position.
BioCorRx Inc. shows negative revenue and net income with current liabilities vastly exceeding current assets, resulting in very low liquidity ratios (current ratio 0.06, cash ratio 0.01). These financial conditions indicate potential solvency and operational risks. Lack of disclosed sector and business details adds to uncertainty about the company's ability to improve its financial health.
There is insufficient publicly disclosed information to assess BioCorRx Inc.'s competitive advantages or moat. The company's financial disclosures indicate operational challenges, but no details on proprietary technology, market position, or barriers to entry are available.
• Liquidity Risk: The company's current liabilities significantly exceed current assets, with a current ratio of 0.06 and cash ratio of 0.01 as of September 30, 2026, indicating potential difficulties in meeting short-term obligations [S2].
• Operational Losses: Negative revenue and net income reported for the latest quarter suggest ongoing operational challenges and potential cash flow constraints [S2].
• Information Transparency: Limited disclosure on business model, sector, and industry reduces clarity on the company's strategic positioning and risk exposure.
Business trends: The company shows ongoing operational losses and liquidity challenges as reflected in recent SEC filings, with limited public information on business activities.
Execution milestones: Monitoring of quarterly financial disclosures and any changes in liquidity or revenue trends will be key to assessing operational stability.
Key risks: Liquidity shortfall, sustained negative revenue and net income, and lack of detailed business model disclosure pose significant risks to financial health.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- BioCorRx Inc. is a publicly traded company with ticker BICX.
- The latest SEC filing is a 10-Q filed on 2026-11-16 covering the period ending 2026-09-30 [S2].
- As of 2026-09-30, the company reported cash and cash equivalents of $111,461 USD and current assets of $528,740 USD [S2].
- Current liabilities as of 2026-09-30 were $9,181,525 USD, resulting in a current ratio of 0.06 and a cash ratio of 0.01, indicating liquidity constraints [S2].
- The company reported negative revenue of -$40,348 USD and a net loss of -$797,134 USD for the period ending 2026-09-30 [S2].
- Basic earnings per share were reported as $0.36, while diluted EPS was -$0.03 for the same period [S2].
- Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].
- Recent news articles related to BioCorRx Inc. or its sector include topics such as agricultural commodity price movements and other unrelated industry news, but no direct recent business developments specific to BioCorRx were identified [N1][N2][N3][N4][N5][N6][N7][N8].
Generated 2026-11-17
- S1 | 2026-03-31 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-11-17 | www.nasdaq.com | Wheat Popping Higher After Ukrainian Strike | https://www.nasdaq.com/articles/wheat-popping-higher-after-ukrainian-strike
- N2 | 2026-11-17 | www.nasdaq.com | Corn Extending Gains to Tuesday Morning | https://www.nasdaq.com/articles/corn-extending-gains-tuesday-morning
- N3 | 2026-11-17 | www.nasdaq.com | Air Industries Group Disavows Tenax Aerospace Press Release Dated November 16, 2026 | https://www.nasdaq.com/articles/air-industries-group-disavows-tenax-aerospace-press-release-dated-november-16-2026
- N4 | 2026-11-17 | www.nasdaq.com | Dermata Therapeutics, Inc. Reports Over 1,000 Orders for Tome Foundational Treatment | https://www.nasdaq.com/articles/dermata-therapeutics-inc-reports-over-1000-orders-tome-foundational-treatment
- N5 | 2026-11-17 | www.nasdaq.com | Essential Properties Realty Trust, Inc. Details Capital Plan and 4Q'26 Investment Activity | https://www.nasdaq.com/articles/essential-properties-realty-trust-inc-details-capital-plan-and-4q26-investment-activity
- N6 | 2026-11-17 | www.nasdaq.com | Disney Increases Dividend By 33%. Here’s What’s Driving the Shift. | https://www.nasdaq.com/articles/disney-increases-dividend-33-heres-whats-driving-shift
- N7 | 2026-08-16 | www.nasdaq.com | Elon Musk Has Said He Wants 25% Voting Control of Tesla to Feel Comfortable Leading Its AI Push. Here's What That Threshold Means for Shareholders. | https://www.nasdaq.com/articles/elon-musk-has-said-he-wants-25-voting-control-tesla-feel-comfortable-leading-its-ai-push
- N8 | 2026-08-16 | www.nasdaq.com | ANZ Group Q3 Cash Profit Rises | https://www.nasdaq.com/articles/anz-group-q3-cash-profit-rises
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


